TG Therapeutics Statistics
TG Therapeutics (NKB2) Stock Statistics & Valuation Metrics
Total Valuation
TG Therapeutics has a market cap or net worth of EUR 8.70B. The enterprise value is EUR 8.95B.
- Market Cap
- EUR 8.70B
- Enterprise Value
- EUR 8.95B
Share Statistics
TG Therapeutics has 151,147,830 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 151,147,830
- Owned by Insiders
- 7.54%
- Owned by Institutions
- 51.38%
Financial Efficiency
TG Therapeutics’s return on equity (ROE) is 0.69 and return on invested capital (ROIC) is 13.54%.
- Return on Equity (ROE)
- 0.69
- Return on Assets (ROA)
- 0.42
- Return on Invested Capital (ROIC)
- 13.54%
- Return on Capital Employed (ROCE)
- 0.14
- Revenue Per Employee
- 1.54M
- Profits Per Employee
- 1.12M
- Employee Count
- 399
- Asset Turnover
- 0.58
- Inventory Turnover
- 0.80
Valuation Ratios
The current PE Ratio of TG Therapeutics is 86.27. TG Therapeutics’s PEG ratio is -1.14.
- PE Ratio
- 86.27
- PS Ratio
- 10.96
- PB Ratio
- 15.81
- Price to FCF
- 114.97
- Price to Operating Cash Flow
- 104.88
- PEG Ratio
- -1.14
Income Statement
In the last 12 months, TG Therapeutics had revenue of 616.29M and earned 447.18M in profits. Earnings per share was 3.10.
- Revenue
- 616.29M
- Gross Profit
- 515.57M
- Operating Income
- 123.32M
- Pretax Income
- 107.39M
- Net Income
- 447.18M
- EBITDA
- 134.36M
- Earnings Per Share (EPS)
- 3.10
Cash Flow
In the last 12 months, operating cash flow was 86.26M and capital expenditures -693,000, giving a free cash flow of 85.56M billion.
- Operating Cash Flow
- 86.26M
- Free Cash Flow
- 85.56M
- Free Cash Flow per Share
- 0.61
Dividends & Yields
TG Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.85%
- Earnings Yield
- 1.14%
Stock Price Statistics
- Beta
- 0.27
- 52-Week Price Change
- 111.59%
- 50-Day Moving Average
- 48.82
- 200-Day Moving Average
- 38.63
- Relative Strength Index (RSI)
- 65.84
- Average Volume (3m)
- 457
Important Dates
TG Therapeutics upcoming earnings date is Mar 02, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 09, 2026
- Next Earnings Date
- Mar 02, 2027
- Ex-Dividend Date
- ―
Financial Position
TG Therapeutics as a current ratio of 4.10, with Debt / Equity ratio of 40.24%
- Current Ratio
- 4.10
- Quick Ratio
- 3.29
- Debt to Market Cap
- 0.06
- Net Debt to EBITDA
- 1.35
- Interest Coverage Ratio
- 4.61
Taxes
In the past 12 months, TG Therapeutics has paid -339.79M in taxes.
- Income Tax
- -339.79M
- Effective Tax Rate
- -3.16
Enterprise Valuation
TG Therapeutics EV to EBITDA ratio is 54.45, with an EV/FCF ratio of 121.76.
- EV to Sales
- 11.61
- EV to EBITDA
- 54.45
- EV to Free Cash Flow
- 121.76
- EV to Operating Cash Flow
- 120.79
Balance Sheet
TG Therapeutics has EUR 504.67M in cash and marketable securities with EUR 754.37M in debt, giving a net cash position of -EUR 249.70M billion.
- Cash & Marketable Securities
- EUR 504.67M
- Total Debt
- EUR 754.37M
- Net Cash
- -EUR 249.70M
- Net Cash Per Share
- -EUR 1.65
- Tangible Book Value Per Share
- EUR 4.06
Margins
Gross margin is 82.74%, with operating margin of 21.48%, and net profit margin of 11.81%.
- Gross Margin
- 82.74%
- Operating Margin
- 21.48%
- Pretax Margin
- 16.66%
- Net Profit Margin
- 11.81%
- EBITDA Margin
- 21.31%
- EBIT Margin
- 21.28%
Analyst Forecast
The average price target for TG Therapeutics is EUR 68.08, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 68.08
- Price Target Upside
- 15.77% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- 61.37%
- EPS Growth Forecast
- -75.69%
Scores
- Smart Score
- 7
- AI Score
- ―
